Starling Oncology, Inc. Remaining Share Repurchase Authorization
Starling Oncology, Inc. (DFPH) had Remaining Share Repurchase Authorization of $11.00 million as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2023-11-08
- 2022-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $11.00M.
- 2022-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $11.00M.
- 2022-05-10: Stock Repurchase Program, Remaining Authorized Repurchase Amount $20.00M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2022-09-30 | $11.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $11.00M 10-Q · filed 2022-08-09 |
| 2022-05-10 | $20.00M 10-Q · filed 2023-11-08 |